OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dunavin on Treatment Considerations in Myelofibrosis

January 10th 2020

Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.

Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast Cancer

January 10th 2020

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma

January 10th 2020

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCL

January 10th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Backes on Financial Toxicity Considerations in Ovarian Cancer

January 10th 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

January 10th 2020

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Dr. Fakhri on Selecting the Optimal Treatment in CLL

January 10th 2020

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.

Dr. Brammer on the Importance of MRD in Relapsed/Refractory ALL

January 10th 2020

Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.

Dr. He on Future Treatment for Patients With Hepatocellular Carcinoma

January 10th 2020

Aiwu Ruth He, MD, discusses the combination regimen of bevacizumab and atezolizumab in patients with advanced-stage hepatocellular carcinoma.

Dr. Backes on the FILM Trial in Endometrial Cancer

January 9th 2020

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

Dr. Goetz on the Use of ctDNA in the MONARCH-3 Trial in HR+/HER2- Breast Cancer

January 9th 2020

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

January 9th 2020

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

January 9th 2020

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

January 9th 2020

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

January 9th 2020

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

Dr. Schlumbrecht on the Challenges of Diagnosing Uterine Leiomyosarcoma

January 9th 2020

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

Dr. Mims on Performing Molecular Profiling at Diagnosis in AML

January 9th 2020

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.

Dr. Heath on Recent Approvals in Nonmetastic Prostate Cancer

January 9th 2020

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Dr. Chaudhry on Unmet Needs in Relapsed/Refractory Multiple Myeloma

January 9th 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.